SCHEMBL7656534

SCHEMBL7656534

COCCOCCSc1ccc(C(=O)Nc2ccc(C=Cc3ccc(NC(=O)c4ccc(SCCOCCOC)c(S(=O)(=O)N5CCOCC5)c4)cc3S(=O)(=O)O)c(S(=O)(=O)O)c2)cc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.48
SMN1; SMN2 Q16637 7/20 0.48
MAPK1 P28482 6/20 0.48
ALDH1A1 P00352 6/20 0.48
KMT2A Q03164 5/20 0.47
MAPT P10636 5/20 0.47
TSHR P16473 3/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
USP2 O75604 2/20 0.47
MITF O75030 1/20 0.47
NTSR1 P30989 1/20 0.47
MEN1 O00255 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 2/20 0.46
CNR2 P34972 2/20 0.46
CNR1 P21554 1/20 0.46
NPC1 O15118 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7656425 1.00 LMNA (0.48) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7663212 0.95 LMNA (0.51) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7663111 0.95 LMNA (0.51) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7658971 0.89 CNR2 (0.53) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7659042 0.89 CNR2 (0.53) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7663948 0.88 SMN1; SMN2 (0.49) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7663870 0.88 SMN1; SMN2 (0.49) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7669354 0.87 LMNA (0.56) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL7659464 0.87 LMNA (0.56) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A
SCHEMBL8022405 0.87 KMT2A (0.54) LMNASMN1; SMN2MAPK1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US claimed
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US disclosed
US-6355633-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists FSHR, GNRHR, LHCGR LMNA 3330/4885SMN1; SMN2 2927/4885MAPK1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.